Petros Pharmaceuticals Appoints Experienced CFO as New Principal Financial Officer

summarizeSummary

Petros Pharmaceuticals announced a change in its top financial leadership, with the mutual departure of Mitchell Arnold and the immediate appointment of Robert Weinstein as the new Principal Financial Officer and Chief Accounting Officer.

check_boxKey Events · Executive and Board Changes · PTPI

• Mutual Separation of Key Financial Officer

  Mitchell Arnold, who served as Vice President of Finance, Principal Accounting Officer, and Principal Financial Officer, mutually separated from the company, effective June 18, 2026.

• Severance Package Details

  Mr. Arnold will receive a severance payment of $38,500, payment for 12.5 accrued unused PTO days totaling $11,105.77, acceleration of 3,000 unvested restricted shares, a $100 tax payment, and up to two months of COBRA premium coverage.

• Appointment of Experienced Successor

  Robert Weinstein was immediately appointed as Chief Accounting Officer, Principal Financial Officer, and Principal Accounting Officer. Mr. Weinstein brings over 30 years of accounting and finance experience, including prior CFO roles at publicly-traded biotechnology companies.

auto_awesomeAnalysis · PTPI · Life Sciences

Petros Pharmaceuticals, a company facing significant financial challenges and going concern doubts, has replaced its Vice President of Finance, Principal Accounting Officer, and Principal Financial Officer. While the mutual departure of a key financial executive can introduce some disruption, the immediate appointment of Robert Weinstein, an experienced CFO with a background in publicly-traded biotechnology companies, is a positive development. His expertise could be crucial in navigating the company's liquidity issues and improving its financial stability.